In small-animal cardiology applications where ventricular rate control is required in atrial fibrillation secondary to myxomatous mitral valve disease, Folia Digitalis powder is incorporated into low-dose tablet lines through sequential geometric dilution rather than direct bulk addition. The material is a standardized botanical drug substance, not a single chemical entity, and the batch potency expressed as total cardenolides calculated as digitoxin is the controlling input for charge-in. At a lot potency of 0.28% total cardenolides as digitoxin, a 0.1 mg digitoxin-equivalent dose requires 35.7 mg of API per tablet; a 0.2 mg target at 0.30% potency requires 66.7 mg per tablet. Depending on prescription strength and tablet mass, the API fraction occupies between 10% w/w and 50% w/w in a 100–150 mg tablet. The dry blending process is staged as 1:10 API-to-lactose preblend in a 50 L double-cone blender at 70% fill volume, then diluted with microcrystalline cellulose and crospovidone. Blend uniformity samples are taken at 10 positions after 10, 20, and 30 min; the acceptance criterion is assay RSD ≤5.0%. Final lubrication with 0.5% w/w magnesium stearate is limited to 3 min to avoid excessive hydrophobic surface coating. Compression is run on a rotary press with 8 mm round punches, 5 kN precompression and 12–15 kN main compression; target hardness is 6–8 kp and friability is not more than 1.0%. Wet granulation is avoided because aqueous binder solutions create localised alkaline microenvironments and extend drying heat exposure. Compendial compliance is anchored to USP <561> for botanical identity and adulteration, the USP Digitalis monograph for bioassay potency, USP <905> for content uniformity, and USP <701> for disintegration; manufacturing operations are executed under FDA 21 CFR 210/211 and, where the product is a registered veterinary medicinal product, EU Regulation 2019/6. Final compressed tablet formats are 50 mg, 100 mg, and 150 mg total mass with API mass adjusted per lot potency.

What Limits Capsule Fill-Weight Variability in Feline Cardiology Compounding?

Hard-gelatin capsule lines for feline cardiac patients encounter electrostatic charge accumulation from the cuticular waxes and fine lignocellulose particles of milled foxglove leaf, and this is the principal process bottleneck when the API mass per capsule falls below 25 mg. The API is therefore pre-dispersed by mortar trituration with pregelatinised maize starch at 1:5 to 1:9, then blended with lactose monohydrate and 0.2% w/w colloidal silicon dioxide. Final capsule fill weight is 75–125 mg, with the API portion recalculated from the lot potency; a 0.1 mg cardenolide target at 0.28% potency yields 35.7 mg leaf API per capsule. Powder flow before filling is controlled by angle of repose not exceeding 35° and Hausner ratio not exceeding 1.25. Filling is performed on a semi-automatic tamping-pin capsule machine with size 3 or size 4 hard gelatin capsules, dosing disc 0.25–0.35 mL, and average fill weight checks every 15 min against a ±3% control limit. Ambient RH is held below 50% to prevent powder plugging and capsule shell deformation. Compliance includes USP <905> content uniformity, USP <711> dissolution or USP <701> disintegration per the product-specific method, and FDA 21 CFR 211 finished-product GMP; when prepared as patient-specific compounded capsules, USP <795> governs nonsterile compounding. The capsule line therefore dispenses hard gelatin capsules labeled 25 mg, 50 mg, and 75 mg standardized leaf API.

Dose titration below one-compressed-tablet increments requires an oral liquid in which the same Folia Digitalis API is processed by cold percolation rather than extracted by boiling water, because elevated temperatures accelerate lactone ring hydrolysis and reduce bioassay potency. The standard formulation target is 100 mg/mL of standardized leaf equivalent, delivering 1 USP Digitalis Unit per mL when the API is standardized to 10 USP Digitalis Units/g. The vehicle is prepared with 40–60% v/v ethanol, sorbitol solution, and citrate buffer to maintain pH 5.0–5.5; prolonged exposure to pH above 6.0 is avoided because alkaline conditions degrade the butenolide ring. The percolation column is packed to 70–80% of its bed volume with milled leaf, and the hydroalcoholic menstruum is circulated at ambient temperature until the percolate passes identity and potency tests. Clarification is performed through diatomaceous earth and a 0.45 µm filter, followed by amber-glass filling under nitrogen headspace to limit oxidative degradation. Alcohol content is verified by USP <611>, and microbial quality is tested under USP <61> and USP <62>. Where prepared as a registered oral solution, FDA 21 CFR 210/211 and EU Regulation 2019/6 apply; where compounded, USP <795> applies. Finished oral solution formats are 30 mL amber dropper bottles with calibrated markings at 0.25 mL and 0.5 mL.

When the API Is Milled for Veterinary Compounding Pharmacies and Repackaged Granules

Non-industrial veterinary compounding pharmacies use Folia Digitalis API as a starting material for patient-specific oral solids, so the downstream operation is a controlled comminution and repackaging service rather than a finished pharmaceutical product line. The API is diluted geometrically with lactose monohydrate at 1:10, 1:50, or 1:100, because direct weighing of milligram quantities on a balance with 0.1 mg readability produces unacceptable error at the narrow cardenolide window. The powder is ground in an electric mortar grinder or a low-speed blade mill, then passed through 180 µm and 125 µm stainless steel sieves to remove coarse vascular fibres; the resulting powder has a controlled particle-size distribution but retains botanical markers required for identity testing. The milled product is dried or maintained to a loss on drying value below 5.0% as determined by USP <731>, then packaged in unit-of-use containers with desiccant. At the B2B level, the API is transferred against a certificate listing bioassay potency, loss on drying, total ash, acid-insoluble ash, heavy metals, pesticide residues, and microbial limits. Standards governing this activity are USP <795> for nonsterile compounding, USP <800> for hazardous drug containment where the facility classifies cardiac glycosides as hazardous, USP <561> for botanical identity, and ICH Q7 where API repackaging falls under GMP. The route supplies patient-specific oral powders, granules, and capsules; it is not authorized for food-producing animals because no maximum residue limit has been established under Regulation (EC) No 470/2009.

Equine Extralabel Use Remains Bound to 21 CFR 530 and Compounding Documentation

Equine cardiology retains a narrow extralabel use of digitalis preparations when the prescribing veterinarian documents that no approved veterinary product is available. Because no commercial Folia Digitalis tablet is registered for equine use in most jurisdictions, the API enters the pharmacy as a bulk powder and is formulated into oral suspensions or pastes on a prescription-specific basis; there is no fixed industrial addition ratio. The pharmacist calculates the API mass from the prescription dose and the lot potency, then triturates the leaf powder with glycerol before dispersing it into a carboxymethylcellulose vehicle hydrated at 0.5–1.0% w/v. The suspension is preserved with potassium sorbate 0.1% w/v, adjusted to pH 5.5 with citrate buffer, and filled into amber bottles labeled for species-specific administration. Compliance records include FDA 21 CFR 530 extralabel use documentation, USP <795> for nonsterile compounding, and EU Regulation 2019/6 provisions for extemporaneous veterinary preparations where applicable. The compounded outputs are oral suspensions, pastes, and capsules for individual equine patients; this route is not authorised for equines intended for human consumption. Published data for this specific configuration is limited, and batch release is based on prescription-level verification rather than industrial-scale process validation.

Injectable Feasibility Barriers with Whole-Leaf API and Premix Exclusion

Parenteral dosage forms derived from Folia Digitalis API are not a standard industrial downstream because the leaf matrix contributes endotoxins, insoluble cell-wall polysaccharides, and polyphenolic acids that would require destructive depyrogenation before meeting bacterial endotoxin requirements such as USP <85> and Ph. Eur. 2.6.14. Sterile filtration through 0.22 µm does not remove endotoxin, and autoclaving accelerates degradation of the butenolide ring enough to invalidate bioassay potency; published data for this specific configuration is limited. In veterinary emergency settings, the injectable route is supplied by purified digoxin injection rather than whole-leaf extract, because the single chemical entity can be formulated with defined osmosis, pH, and endotoxin control. Consequently, no validated injectable addition ratio or terminal dosage form exists for Folia Digitalis API. The same restriction applies to medicated feed premix in food-producing species: no maximum residue limit has been established under Regulation (EC) No 470/2009, and the narrow therapeutic index of cardiac glycosides cannot be reconciled with the blend uniformity limits of feed premix. Terminal finished product type: none for whole-leaf injectable or food-animal premix; the API remains confined to oral solid and liquid forms and pharmacy compounding.